Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 3/2015

01-03-2015 | Research Article

Matrine inhibits the growth and induces apoptosis of osteosarcoma cells in vitro by inactivating the Akt pathway

Authors: Gong-Ping Xu, Wei Zhao, Jin-Peng Zhuang, Jia-Ning Zu, Duan-Yang Wang, Fei Han, Zhi-Peng Zhang, Jing-Long Yan

Published in: Tumor Biology | Issue 3/2015

Login to get access

Abstract

Matrine, a natural product, has been demonstrated to be a promising chemotherapeutic drug for some cancers. Using flow cytometric analysis of the cell cycle and apoptosis, we found that matrine inhibited the proliferation and induced apoptosis in the human osteosarcoma (OS) cell lines MG63, HOS, U2OS, and SAOS2 in vitro in a dose-dependent manner. We therefore assessed the role of the serine/threonine kinase Akt in the regulation of matrine-mediated cell growth inhibition and apoptosis induction in human OS cell lines. After treatment for 48 h, matrine induced G0/G1-stage cell cycle arrest in MG63, U2OS, and SAOS2 cells associated with an increase in the expression of p27Kip1 and a decrease in the expression of Akt, glycogen synthase kinase 3 (GSK3)-β (Ser9), and cyclin D1. Furthermore, the pro-apoptotic factor Bax was upregulated. Overall, our findings suggest that matrine may be an effective anti-osteosarcoma drug due to its ability to inhibit proliferation and induce apoptosis in OS cells, possibly through the involvement of Akt signaling.
Literature
1.
Li Y, Wang B, Zhou C, Bi Y. Matrine induces apoptosis in angiotensin II-stimulated hyperplasia of cardiac fibroblasts: effects on Bcl-2/Bax expression and caspase-3 activation. Basic Clin Pharmacol Toxicol. 2007;101:1–8.CrossRefPubMed
2.
Sun YN, Xu B, Huang ZQ, Huang CX. Effect of matrine on levels of TGF-β1, TNF-α, HA and PcIII in sera of chronic hepatitis B patients. Chin J Mod Med. 2004;14:41–5.
3.
Li X, Zhou R, Zheng P, Yan L, Wu Y, Xiao X, et al. Cardioprotective effect of matrine on isoproterenol-induced cardiotoxicity in rats. J Pharm Pharmacol. 2010;62:514–20.CrossRefPubMed
4.
Liang CZ, Zhang JK, Shi Z, Liu B, Shen CQ, Tao HM. Matrine induces caspase-dependent apoptosis in human osteosarcoma cells in vitro and in vivo through the upregulation of Bax and Fas/FasL and downregulation of Bcl-2. Cancer Chemother Pharmacol. 2012;69:317–31.CrossRefPubMed
5.
Luo C, Zhu Y, Jiang T, Lu X, Zhang W, Jing Q, et al. Matrine induced gastric cancer MKN45 cells apoptosis via increasing pro-apoptotic molecules of Bcl-2 family. Toxicology. 2007;229:245–52.CrossRefPubMed
6.
Zhang L, Wang T, Wen X, Wei Y, Peng X, Li H, et al. Effect of matrine on HeLa cell adhesion and migration. Eur J Pharmacol. 2007;563:69–76.CrossRefPubMed
7.
Yu P, Liu Q, Liu K, Yagasaki K, Wu E, Zhang G. Matrine suppresses breast cancer cell proliferation and invasion via VEGF-Akt-NF-kappaB signaling. Cytotechnology. 2009;59:219–29.CrossRefPubMedPubMedCentral
8.
Han Y, Zhang S, Wu J, Yu K, Zhang Y, Yin L, et al. Matrine induces apoptosis of human multiple myeloma cells via activation of the mitochondrial pathway. Leuk Lymphoma. 2010;51:1337–46.CrossRefPubMed
9.
Liu T, Song Y, Chen H, Pan S, Sun X. Matrine inhibits proliferation and induces apoptosis of pancreatic cancer cells in vitro and in vivo. Biol Pharm Bull. 2010;33:1740–5.CrossRefPubMed
10.
Kandel ES, Hay N. The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp Cell Res. 1999;253:210–29.CrossRefPubMed
11.
Al-Shami A, Naccache PH. Granulocyte-macrophage colony-stimulating factor-activated signaling pathways in human neutrophils. Involvement of Jak2 in the stimulation of phosphatidylinositol 3-kinase. J Biol Chem. 1999;274:5333–8.CrossRefPubMed
12.
Gardai S, Whitlock BB, Helgason C, Ambruso D, Fadok V, Bratton D, et al. Activation of SHIP by NADPH oxidase-stimulated Lyn leads to enhanced apoptosis in neutrophils. J Biol Chem. 2002;277:5236–46.CrossRefPubMed
13.
Hideshima T, Nakamura N, Chauhan D, Anderson KC. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene. 2001;20:5991–6000.CrossRefPubMed
14.
Ye X, Guo Y, Zhang Q, Chen W, Hua X, Liu W, et al. βKlotho suppresses tumor growth in hepatocellular carcinoma by regulating Akt/GSK-3β/cyclin D1 signaling pathway. PLoS One. 2013;8:e55615.CrossRefPubMedPubMedCentral
15.
Lu M, Gong X, Lu Y, Guo J, Wang C, Pan Y. Molecular cloning and functional characterization of a cell-permeable superoxide dismutase targeted to lung adenocarcinoma cells. Inhibition cell proliferation through the Akt/p27kip1 pathway. J Biol Chem. 2006;281:13620–7.CrossRefPubMed
16.
Gibson S, Tu S, Oyer R, Anderson SM, Johnson GL. Epidermal growth factor protects epithelial cells against Fas-induced apoptosis. Requirement for Akt activation. J Biol Chem. 1999;274:17612–8.CrossRefPubMed
17.
Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev. 1999;13:2905–27.CrossRefPubMed
18.
Aikin R, Rosenberg L, Maysinger D. Phosphatidylinositol 3-kinase signaling to Akt mediates survival in isolated canine islets of Langerhans. Biochem Biophys Res Commun. 2000;277:455–61.CrossRefPubMed
19.
Yamaguchi H, Wang HG. The protein kinase PKB/Akt regulates cell survival and apoptosis by inhibiting Bax conformational change. Oncogene. 2001;20:7779–86.CrossRefPubMed
20.
Tsuruta F, Masuyama N, Gotoh Y. The phosphatidylinositol 3-kinase-Akt pathway, PI3K suppresses Bax translocation to mitochondria. J Biol Chem. 2002;277:14040–7.CrossRefPubMed
21.
Zhao W, Zhou SF, Zhang ZPXGP, Li XB, Yan JL. Gambogic acid inhibits the growth of osteosarcoma cells in vitro by inducing apoptosis and cell cycle arrest. Oncol Rep. 2011;25:1289–95.PubMed
22.
Wang JS, Ji AF, Wan HJ, Lu YL, Yang JZ, Ma LL, et al. Gene silencing of beta-catenin by RNAi inhibits proliferation of human esophageal cancer cells by inducing G0/G1 cell cycle arrest. Asian Pac J Cancer Prev. 2012;13:2527–32.CrossRefPubMed
23.
Hernandez-Hernandez OT, Camacho-Arroyo I. Regulation of gene expression by progesterone in cancer cells: effects on cyclin D1, EGFR and VEGF. Mini-Rev Med Chem. 2013;13:635–42.CrossRefPubMed
24.
Jiang QQ, Liu B, Yuan T. MicroRNA-16 inhibits bladder cancer proliferation by targeting cyclin D1. Asian Pac J Cancer Prev. 2013;14:4127–30.CrossRefPubMed
25.
Zhu P, Chen JM, Chen SZ, Zhang C, Zheng SY, Long G, et al. Matrine inhibits vascular smooth muscle cell proliferation by modulating the expression of cell cycle regulatory genes. Acta Pharmacol Sin. 2010;31:1329–35.CrossRefPubMedPubMedCentral
26.
Zhang JQ, Li YM, Liu T, He WT, Chen YT, Chen XH, et al. Antitumor effect of matrine in human hepatoma G2 cells by inducing apoptosis and autophagy. World J Gastroenterol. 2010;16:4281–90.CrossRefPubMedPubMedCentral
27.
Lindsten T, Ross AJ, King A, Zong WX, Rathmell JC, Shiels HA, et al. The combined functions of proapoptotic Bcl-2 family members Bak and Bax are essential for normal development of multiple tissues. Mol Cell. 2000;6:1389–99.CrossRefPubMedPubMedCentral
28.
Kennedy SG, Kandel ES, Cross TK, Hay N. Akt/Protein kinase B inhibits cell death by preventing the release of cytochrome c from mitochondria. Mol Cell Biol. 1999;19:5800–10.CrossRefPubMedPubMedCentral
29.
Gardai SJ, Hildeman DA, Frankel SK, Whitlock BB, Frasch SC, Borregaard N, et al. Phosphorylation of Bax Ser184 by Akt regulates its activity and apoptosis in neutrophils. J Biol Chem. 2004;279:21085–95.CrossRefPubMed
30.
Merhi F, Tang R, Piedfer M, Mathieu J, Bombarda I, Zaher M, et al. Hyperforin inhibits Akt1 kinase activity and promotes caspase-mediated apoptosis involving Bad and Noxa activation in human myeloid tumor cells. PLoS One. 2011;6:e25963.CrossRefPubMedPubMedCentral
31.
Segerstrom L, Baryawno N, Sveinbjörnsson B, Wickström M, Elfman L, Kogner P, et al. Effects of small molecule inhibitors of PI3K/Akt/mTOR signaling on neuroblastoma growth in vitro and in vivo. Int J Cancer. 2011;129:2958–65.CrossRefPubMed
32.
Yeramian A, Sorolla A, Velasco A, Santacana M, Dolcet X, Valls J, et al. Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway. Int J Cancer. 2012;130:967–78.CrossRefPubMed
Metadata
Title
Matrine inhibits the growth and induces apoptosis of osteosarcoma cells in vitro by inactivating the Akt pathway
Authors
Gong-Ping Xu
Wei Zhao
Jin-Peng Zhuang
Jia-Ning Zu
Duan-Yang Wang
Fei Han
Zhi-Peng Zhang
Jing-Long Yan
Publication date
01-03-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 3/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2764-5

Other articles of this Issue 3/2015

Tumor Biology 3/2015 Go to the issue

Research Article

MiR-451 inhibits cell growth and invasion by targeting CXCL16 and is associated with prognosis of osteosarcoma patients

Research Article

Predictive impact of genetic polymorphisms in DNA repair genes on susceptibility and therapeutic outcomes to colorectal cancer patients

Research Article

MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1

Review

Immunotherapy for lung cancer: for whom the bell tolls?

Review

Hedgehog pathway aberrations and gastric cancer; evaluation of prognostic impact and exploration of therapeutic potentials

Research Article

Identification of OLIG2 as the most specific glioblastoma stem cell marker starting from comparative analysis of data from similar DNA chip microarray platforms
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits